A similar result was obtained using a different IGF1R inhibitor, genetic knockout of endogenous IGF1R, in multiple mouse and human primary glioma cell lines with different genetic mutations (Figure S11C–G, Supporting Information). The gene discussed is IGF1R; the disease is central nervous system cancer.